Literature DB >> 32822758

Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.

K D Rysenkova1, P S Klimovich2, A A Shmakova2, M N Karagyaur3, K A Ivanova4, N A Aleksandrushkina5, V A Tkachuk1, K A Rubina6, E V Semina1.   

Abstract

Urokinase-type plasminogen activator uPA and its receptor (uPAR) are the central players in extracellular matrix proteolysis, which facilitates cancer invasion and metastasis. EGFR is one of the important components of uPAR interactome. uPAR/EGFR interaction controls signaling pathways that regulate cell survival, proliferation and migration. We have previously established that uPA binding to uPAR stimulates neurite elongation in neuroblastoma cells, while blocking uPA/uPAR interaction induces neurite branching and new neurite formation. Here we demonstrate that blocking the uPA binding to uPAR with anti-uPAR antibody decreases the level of pEGFR and its downstream pERK1/2, but does increase phosphorylation of Akt, p38 and c-Src Since long-term uPAR blocking results in a severe DNA damage, accompanied by PARP-1 proteolysis and Neuro2a cell death, we surmise that Akt, p38 and c-Src activation transmits a pro-apoptotic signal, rather than a survival. Serum deprivation resulting in enhanced neuritogenesis is accompanied by an upregulated uPAR mRNA expression, while EGFR mRNA remains unchanged. EGFR activation by EGF stimulates neurite growth only in uPAR-overexpressing cells but not in control or uPAR-deficient cells. In addition, AG1478-mediated inhibition of EGFR activity impedes neurite growth in control and uPAR-deficient cells, but not in uPAR-overexpressing cells. Altogether these data implicate uPAR as an important regulator of EGFR and ERK1/2 signaling, representing a novel mechanism which implicates urokinase system in neuroblastoma cell survival and differentiation.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; EGFR; Neuritogenesis; Neuro2a; Neuroblastoma; Urokinase plasminogen activator receptor

Year:  2020        PMID: 32822758     DOI: 10.1016/j.cellsig.2020.109741

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  9 in total

1.  IL4 stimulated macrophages promote axon regeneration after peripheral nerve injury by secreting uPA to stimulate uPAR upregulated in injured axons.

Authors:  Yuki Matsui; Ken Kadoya; Yusuke Nagano; Takeshi Endo; Masato Hara; Gen Matsumae; Tomoaki Suzuki; Yasuhiro Yamamoto; Mohamad Alaa Terkawi; Norimasa Iwasaki
Journal:  Cell Mol Life Sci       Date:  2022-05-10       Impact factor: 9.261

2.  Urokinase-Type Plasminogen Activator Enhances the Neuroprotective Activity of Brain-Derived Neurotrophic Factor in a Model of Intracerebral Hemorrhage.

Authors:  Stalik Dzhauari; Svetlana Litvinova; Anastasia Efimenko; Natalia Aleksandrushkina; Nataliya Basalova; Maxim Abakumov; Natalia Danilova; Pavel Malkov; Vadim Balabanyan; Tatiana Bezuglova; Viktor Balayants; Maxim Mnikhovich; Mikhail Gulyaev; Mariya Skryabina; Vladimir Popov; Dmitry Stambolsky; Tatiana Voronina; Vsevolod Tkachuk; Maxim Karagyaur
Journal:  Biomedicines       Date:  2022-06-08

3.  Identification of a Novel Small RNA Encoded in the Mouse Urokinase Receptor uPAR Gene (Plaur) and Its Molecular Target Mef2d.

Authors:  Karina D Rysenkova; Konstantin E Troyanovskiy; Polina S Klimovich; Taisiya R Bulyakova; Ekaterina M Shelomentseva; Anna A Shmakova; Daria Yu Tanygina; Olga I Ivashkina; Konstantin V Anokhin; Maxim N Karagyaur; Maria I Zvereva; Kseniya A Rubina; Vsevolod A Tkachuk; Ekaterina V Semina
Journal:  Front Mol Neurosci       Date:  2022-07-06       Impact factor: 6.261

4.  CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anastasia Chillà; Mario Del Rosso; Gabriella Fibbi; Francesca Scavone; Elena Andreucci; Silvia Peppicelli; Francesca Bianchini; Lido Calorini; Anna Li Santi; Pia Ragno; Francesca Margheri; Anna Laurenzana
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

5.  Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis.

Authors:  Anna A Shmakova; Polina S Klimovich; Karina D Rysenkova; Vladimir S Popov; Anna S Gorbunova; Anna A Karpukhina; Maxim N Karagyaur; Kseniya A Rubina; Vsevolod A Tkachuk; Ekaterina V Semina
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

Review 6.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

7.  PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma.

Authors:  Mulin Liu; Siyi Chen; Aihui Zhang; Qin Zheng; Juan Fu
Journal:  J Inflamm Res       Date:  2021-09-15

Review 8.  Update on Novel Targeted Therapy for Pleural Organization and Fibrosis.

Authors:  Torry A Tucker; Steven Idell
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 9.  The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications.

Authors:  Irena Horwacik
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.